May 19, 2025 | Biosimilar, Cancer, Drug costs, Generic Drugs, GLP-1s, Rx Costs, Study
Prescription drug spending in the U.S. climbed 10.2% in 2024, reaching nearly $806 billion, according to a report from the American Society of Health-System Pharmacists. A significant portion of this growth is attributed to the rapid rise of...
May 5, 2025 | Legislation, News, Pharmacies, Pharmacy Benefits Manager (PBM), State legislation
On April 16, Arkansas became the first state to ban pharmacy benefit managers (PBMs) from acquiring an interest in – or otherwise directly or indirectly holding a permit for the retail sale of – prescription drugs, including mail-order...
Apr 21, 2025 | Biosimilar, Cost Savings, Drug costs, Humira, Rx Costs, Savings, Stelara
Earlier this month, MedBen Rx clients and their brokers were emailed about an opportunity to receive preferred pricing for the biosimilar for the anti-inflammatory medication Stelara. Depending on the dosage, this biosimilar can reduce the cost of the medication by...
Mar 24, 2025 | Drug costs, Lawsuits, News, Pharmacy Benefits Manager (PBM), Prescription drugs, Rx Costs
Current and former employees are suing the financial services firm JPMorgan for allowing inflated drug prices through its partnership with pharmacy benefits manager (PBM) CVS Caremark. The plaintiffs claim that poor PBM oversight led to unnecessarily high prescription...
Mar 10, 2025 | Compliance, Consolidated Appropriations Act of 2021 (CAA), Regulatory, RxDC report
As you may recall, the Consolidated Appropriations Act of 2021 (CAA) requires group health plans to submit to the Centers for Medicare & Medicaid Services information about prescription drugs and health care spending. This data submission is called RxDC (for...
